TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd ( (DRTS) ) has provided an announcement.
On December 2, 2025, Alpha Tau Medical Ltd. announced that it received FDA approval to initiate a pilot study for treating patients with locally recurrent prostate cancer using its Alpha DaRT technology. This marks the company’s fifth active U.S. IDE, expanding its reach in the U.S. market. The trial will enroll up to 12 U.S. patients and aims to evaluate the safety and efficacy of Alpha DaRT as a local salvage therapy, offering an alternative to current treatments for recurrent prostate cancer. This development could significantly impact Alpha Tau’s operations and industry positioning, as it addresses a critical need for new treatments in the prostate cancer segment.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company that focuses on the research, development, and potential commercialization of Alpha DaRT® technology for the treatment of solid tumors. The technology, which was initially developed by professors from Tel Aviv University, aims to deliver highly potent alpha-radiation to solid tumors while sparing healthy tissue.
Average Trading Volume: 62,183
Technical Sentiment Signal: Buy
Current Market Cap: $320.2M
For an in-depth examination of DRTS stock, go to TipRanks’ Overview page.